Dr. Laura Kate Mackay: Are TRM Cells the Future of Vaccine and Cancer Treatments?

The Michelson Medical Research Foundation and the Human Immunome Project (formerly Human Vaccines Project) hosted the first Annual Conference on the Future of Vaccine Development on June 27, 2018, at the USC Michelson Center for Convergent Bioscience.

The conference brought together leading scientists and researchers from around the world to discuss the latest advances in vaccines and to explore new ways to accelerate the development of vaccines against some of the world's most threatening diseases.

Michelson Prize Recipient: Dr. Laura Kate Mackay

Dr. Laura Kate Mackay, is a world-leading immunologist at the Peter Doherty Institute for Infection and Immunity at the University of Melbourne. Her research focuses on tissue-resident memory T cells (TRM cells), which are long-lived immune cells that reside in tissues throughout the body and play a critical role in protecting us from infection and cancer.

Targeting Tissue-Resident Immune Cells for Enhanced Immune Protection

In this video clip, Dr. Laura Kate Mackay discusses her research on TRM cells and how they could be targeted to improve immune protection against disease and revolutionize the development of new vaccines and cancer therapies.

Learn more about her medical research: https://www.doherty.edu.au/people/professor-laura-mackay.